First Brands Group debt targeted by Apollo Global Management - report
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary at Twist Bioscience Corp (NASDAQ:TWST), sold 269 shares of common stock on September 8, 2025, at a price of $25.76, for a total value of $6929.
The sale was executed to cover tax withholding obligations related to the vesting of Restricted Stock Units, according to a footnote in the SEC filing. These sales are mandated by Twist Bioscience’s equity incentive plans and do not represent discretionary trades by Cho. Following the transaction, Cho directly owns 103,037 shares of Twist Bioscience Corp. With a beta of 2.31 and a strong current ratio of 3.9, InvestingPro subscribers can access 6 additional key insights about TWST’s financial health and market position.
In other recent news, Twist Bioscience Corporation reported a notable 18% increase in revenue for Q3 2025, reaching $96.1 million. Despite this revenue growth, the company posted an adjusted EBITDA loss of $8 million, which nonetheless marks an improvement from the previous fiscal year. In a strategic move, Twist Bioscience appointed Trynka Shineman Blake to its board of directors, where she will also serve on the audit committee. Blake brings extensive experience from her previous role as CEO of Vistaprint, where she significantly increased the company’s revenue.
In analyst updates, JPMorgan lowered its price target for Twist Bioscience to $25, maintaining an Underweight rating. Meanwhile, TD Cowen adjusted its price target to $36, while still rating the stock as a Buy, due to revised fiscal year 2025 guidance related to a key customer’s transition in the Next-Generation Sequencing (NGS) sector. Evercore ISI also reduced its price target to $46, retaining an Outperform rating, citing strong performance in the NGS segment and solid gross margins. These developments provide a comprehensive view of the current state and future expectations for Twist Bioscience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.